Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2022
2021
2020
2019

2022.01.27

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

2022.01.19

Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

2022.01.13

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 11 - 13 of 13

Shareholder Tools

© 2022 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn